Ji Yuejin, Liu Yajun, Hu Jingyi, Cheng Cheng, Xing Jing, Zhu Lei, Shen Hong
Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, China.
Evid Based Complement Alternat Med. 2021 Oct 4;2021:8578615. doi: 10.1155/2021/8578615. eCollection 2021.
Astragali Radix-Curcumae Rhizoma (ARCR), a classic drug pair, has been widely used for the treatment of gastric intraepithelial neoplasia (GIN) in China. However, the underlying mechanisms of this drug pair are still unknown. Thus, elucidating the molecular mechanism of ARCR for treating GIN is imperative.
The active components and targets of ARCR were determined from the TCMSP database, and the differentially expressed genes related to GIN were identified from the GSE130823 dataset. The protein-protein interaction (PPI) network and ARCR-active component-target-pathway network were constructed by STRING 11.0 and Cytoscape 3.7.2, respectively. In addition, a receiver operating characteristic curve (ROC) was conducted to verify the key targets, and enrichment analyses were performed using R software. Molecular docking was carried out to test the binding capacity between core active components and key targets.
31 active components were obtained from ARCR, among which 22 were hit by the 51 targets associated with GIN. Gene Ontology (GO) functional enrichment analysis showed that biological process (BP), molecular function (MF), and cellular component (CC) were most significantly enriched in response to a drug, catecholamine binding, and apical part of the cell, respectively. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis indicated ARCR against GIN through regulation of neuroactive ligand-receptor interaction, nitrogen metabolism, calcium signaling pathway, chemical carcinogenesis-receptor activation, drug metabolism, gap junction, and cancers. In the PPI network, 15 potential targets were identified, of which nine key targets were proven to have higher diagnostic values in ROC. Molecular docking revealed a good binding affinity of active components (quercetin, bisdemethoxycurcumin, and kaempferol) with the corresponding targets (CYP3A4, CYP1A1, HMOX1, DRD2, DPP4, ADRA2A, ADRA2C, NR1I2, and LGALS4).
This study revealed the active components and molecular mechanism by which ARCR treatment is effective against GIN through regulating multipathway, such as neuroactive ligand-receptor interaction, nitrogen metabolism, and calcium signaling pathway.
黄芪 - 莪术是一对经典药对,在中国已被广泛用于治疗胃上皮内瘤变(GIN)。然而,这药对的潜在机制仍不清楚。因此,阐明黄芪 - 莪术治疗GIN的分子机制势在必行。
从中药系统药理学数据库与分析平台(TCMSP)数据库中确定黄芪 - 莪术的活性成分和靶点,并从GSE130823数据集中鉴定与GIN相关的差异表达基因。分别通过STRING 11.0和Cytoscape 3.7.2构建蛋白质 - 蛋白质相互作用(PPI)网络和黄芪 - 莪术活性成分 - 靶点 - 通路网络。此外,绘制受试者工作特征曲线(ROC)以验证关键靶点,并使用R软件进行富集分析。进行分子对接以测试核心活性成分与关键靶点之间的结合能力。
从黄芪 - 莪术中获得31种活性成分,其中22种与51个与GIN相关的靶点匹配。基因本体(GO)功能富集分析表明,生物过程(BP)、分子功能(MF)和细胞成分(CC)分别在对药物的反应、儿茶酚胺结合和细胞顶端部分中最显著富集。京都基因与基因组百科全书(KEGG)通路分析表明,黄芪 - 莪术通过调节神经活性配体 - 受体相互作用、氮代谢、钙信号通路、化学致癌作用 - 受体激活、药物代谢、缝隙连接和癌症来对抗GIN。在PPI网络中,鉴定出15个潜在靶点,其中9个关键靶点在ROC中被证明具有更高的诊断价值。分子对接显示活性成分(槲皮素、双去甲氧基姜黄素和山奈酚)与相应靶点(CYP3A4、CYP1A1、HMOX1、DRD2、DPP4、ADRA2A、ADRA2C、NR1I2和LGALS4)具有良好的结合亲和力。
本研究揭示了黄芪 - 莪术通过调节多途径(如神经活性配体 - 受体相互作用、氮代谢和钙信号通路)有效治疗GIN的活性成分和分子机制。